Fate Therapeutics Inc (NAS:FATE)
$ 3.2432 0.0732 (2.31%) Market Cap: 369.38 Mil Enterprise Value: 79.38 Mil PE Ratio: 0 PB Ratio: 0.87 GF Score: 57/100

Fate Therapeutics Inc Investor Event - Corporate Call Transcript

Nov 15, 2021 / 09:30PM GMT
Release Date Price: $53.73 (-3.80%)
Operator

Good day, and thank you for standing by. Welcome to the Fate Therapeutics Investor Call. (Operator Instructions) I would now like to hand the conference over to your first speaker today, Scott Wolchko. Please go ahead.

J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director

Thank you. Good afternoon. This is Scott Wolchko, President and CEO of Fate Therapeutics. Thank you all for joining us this afternoon to discuss our emerging cell-based cancer immunotherapy pipeline for solid tumors. We hope today's discussion will be informative, and will serve to highlight several areas of interest, including, number one, the unique features of our proprietary iPSC product platform and the distinct advantages it affords in developing multiplexed engineered cell therapies.

Number two, several novel mechanisms of attack that we are exploiting in the fight against solid tumors, including in concert with other immunotherapies that are used as standard of care. Number three, our emerging multiplexed engineered cell-based cancer immunotherapy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot